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Abstract
Introduction: Lymph node ratio (LNR, i.e. the ratio of the number of positive nodes to the total number of nodes excised) is
reported to be superior to the absolute number of nodes involved (pN stage) in classifying patients at high versus low risk
of death following breast cancer. The added prognostic value of LNR over pN in addition to other prognostic factors has
never been assessed.
Methods: All patients diagnosed with lymph node positive, non-metastatic invasive breast cancer at the National University
Hospital (Singapore) and University of Malaya Medical Center (Kuala Lumpur) between 1990–2007 were included (n = 1589).
Overall survival of the patients was estimated by the Kaplan Meier method for LNR [categorized as low (.0 and ,0.2),
intermediate (0.2–0.65) and high (.0.65–1)] and pN staging [pN1, pN2 and pN3]. Adjusted overall relative mortality risks
associated with LNR and pN were calculated by Cox regression. The added prognostic value of LNR over pN was evaluated
by comparing the discriminating capacity (as indicated by the c statistic) of two multivariate models, one including pN and
one including LNR.
Results: LNR was superior to pN in categorizing mortality risks for women $60 years, those with ER negative or grade 3
tumors. In combination with other factors (i.e. age, treatment, grade, tumor size and receptor status), substituting pN by
LNR did not result in better discrimination of women at high versus low risk of death, neither for the entire cohort (c statistic
0.72 [0.70–0.75] and 0.73 [0.71–0.76] respectively for pN versus LNR), nor for the subgroups mentioned above.
Conclusion: In combination with other prognosticators, substitution of pN by LNR did not provide any added prognostic
value for South East Asian breast cancer patients.
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Introduction
Axillary lymph node status is one of the most important
prognostic factors for breast cancer [1,2,3]. Traditionally, axillary
lymph node status is classified according to the American Joint
Committee on Cancer (AJCC) breast cancer staging system, which
is based on the number of positive axillary lymph nodes [4] where
pN0 indicates zero positive nodes, pN1 1–3 positive nodes, pN2 4–
9 positive nodes and pN3$10 positive nodes. This pN stage is
restricted by the number of nodes excised [5] which in turn
depends upon the surgical approach to axillary dissection, the
expertise of the surgeon as well as the pathologists’ experience and
thoroughness. Variation in these factors can lead to large
differences in the number of lymph nodes retrieved across
institutions thereby influencing staging.
Increasing evidence suggests that the Lymph Node Ratio (LNR)
(the ratio of the number of positive nodes to the total number of
nodes excised), is a superior prognostic indicator compared to the
absolute number of nodes involved [6,7,8,9,10]. However some
studies have shown no difference in prognostic value for LNR over
pN [11]. Vinh Hung et al showed that LNR, categorized as low.0
and ,0.2, intermediate 0.2 to 0.65 and high risk .0.65 to 1, was
better at predicting breast cancer specific mortality than pN
staging [6]. This conclusion was based on the fact that confidence
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intervals for the adjusted hazard ratios did not overlap for the
intermediate and high category LNR groups but did so for the
pN2 and pN3 groups. A study from Korea showed no overall
difference between LNR and pN staging in categorizing poor,
intermediate and good survivors, except for certain subgroups, i.e.
women aged,35 years, HER2 over expressing and triple negative
tumors [10]. Other studies conducted in different populations also
suggested that LNR was a significant and independent predictor of
outcome for breast cancer patients [7,8,9,12,13].
Prognostication, however, is a multivariable process, as the
outcome of a disease is determined by a variety of (sometimes
interacting) factors, and breast cancer is no exception. In addition
to axillary lymph node status, prognosis is determined by a variety
of factors, including, age, tumor size, grade, receptors status and
treatment. Despite the large number of studies that have addressed
LNR, not one has assessed the added prognostic value of LNR
over pN in predicting overall survival after breast cancer. Via this
study we aim to assess the added prognostic value of LNR over pN
staging in the South East Asian setting by comparing the pN and
LNR prediction models in terms of (1) predictive power, (2)
discrimination and (3) net reclassification improvement of patient
into appropriate risk categories of all cause mortality.
Methods
Data for this study were obtained from the Singapore Malaysia
Hospital-based Breast Cancer Registry [14]. This registry com-
bines data from the National University Hospital (NUH) breast
cancer registry, Singapore and the University of Malaya Medical
Center (UMMC) breast cancer registry, Kuala Lumpur, Malaysia.
The NUH breast cancer registry started in 1995 and contains
information on 2,449 consecutive breast cancer patients diagnosed
between 1990 and 2007. The UMMC breast cancer registry
started in 1993 contains information on 3,320 patients diagnosed
between 1993 and 2007. Details on both these registries are
described elsewhere [14,15]. In both centers, patients were
monitored through follow-up in the specialist outpatient clinics.
Data on mortality were obtained from the hospitals’ medical
records and by linkage with the respective death registries. Follow
up for each patient was calculated from the date of diagnosis to the
date of death or end of follow up (July 2010 for NUH patients and
November 2010 for UMMC patients). Both the registries had
approval from their respective ethics review boards.
We selected women diagnosed with non metastatic primary
invasive breast cancer, with information on the number of excised
and the number of positive axillary lymph nodes. Patients
receiving neoadjuvant chemotherapy (N= 312), patients with a
node negative (pN0) axilla (N= 2352), patients with missing
information on exact number of lymph nodes involved (N= 664),
with in situ breast cancer (N= 317) and stage IV disease (N= 535)
were excluded. In total 1589 patients were included for analysis.
Information recorded for each patient included age at diagnosis,
ethnicity (Chinese, Malay, Indian or others), year of diagnosis,
place of diagnosis (Singapore, Kuala Lumpur), date of death or
date of last contact. Tumor characteristics included tumor size
(,2 cm, 2–5 cm, .5 cm, unknown), estrogen (ER) and proges-
terone receptor (PR) status (positive i.e., $10% of epithelial tumor
cells expressing receptors, negative and unknown), grade (good,
moderate, poor, unknown). In terms of axillary dissection, we
collected information on total number of axillary nodes examined
and number of positive axilary nodes. LNR was categorized into
three categories including, low (.0 and,0.2), intermediate (0.2 to
0.65) and high category (.0.65 to 1) groups as previously reported




Life table analysis was performed to calculate survival proba-
bilities for the three pN categories and the three LNR categories.
After testing for proportionality, we performed univariate Cox
proportional hazard analysis to identify variables that were
significantly associated with all cause mortality. Multivariate Cox
proportional hazard analysis was applied 1) to calculate adjusted
mortality risks and 2) to identify which combination of factors best
predicted overall survival. For this we entered all variables
univariately associated with overall survival with a p-value ,0.2
into the model and used stepwise backward regression and
maximum likelihood method to find the optimal fit. Internal
validation of each model was done by bootstrap resampling.
Two models (A and B) were constructed. Each model contained
the same baseline variables, i.e., age, radiotherapy, surgery type,
grade and tumor size (base model). Model A contained pN stage in
addition to the base model variables while Model B contained
LNR in addition to the base model variables. From the final
models, adjusted Hazard Ratio for pN and LNR were derived.
Base model : age, radiotherapy, surgery type, grade and tumor
size.
Model A: age, radiotherapy, surgery type, grade, tumor size and
pN stage.
Model B: age, radiotherapy, surgery type, grade, tumor size and
LNR.
Discrimination and Caliberation of Prediction Models
In order to ascertain the added prognostic value of LNR over
pN, we compared the discriminative capacity of model A with
model B. Discrimination indicates how well the model is able to
distinguish between patients who will experience the outcome
(death) and those who will not. Discrimination was assessed by the
Concordance (c) statistic, the interpretation of which is equivalent
to the area under the receiver operating characeristic (ROC)
curve, that is, a c statistic of 0.5 indicates no discrimination above
chance, whereas a c statistic of 1.0 indicates perfect discrimination.
Comparison of c statistics between the model including pN Stage
(Model A) with the one including LNR (Model B) tells whether one
model is better in discriminating between poor and good survivors,
and thus superior in predicting survival. Model calibration–the
agreement between predicted risks and observed mortality risks–
was assessed using the Hosmer Lemeshow test by comparing the
predicted survival and the observed survival at 3-year follow-up.
Net Reclassification Improvement of Patients Based on
the Prediction Models
Finally, the c statistic has been criticized for being insensitive in
comparing models and for having little direct clinical relevance.
Therefore, we calculated the Net Reclassification Improvement
(NRI), which assesses the ability of a model including a new
prognostic marker (LNR - model B) to more accurately reclassify
individuals into higher or lower risk(of death) category compared
to model A, i.e., to check whether model B was better at correctly
reclassifying patients into high risk and low risk groups based on
their predicted survival probability as compared to model A. The
NRI is the difference in proportions of patients moving up and
down risk categories (high, moderate and low risk of mortality)
among patients with the event of interest (death) versus those
without (in our case patients who died within 3 years of follow up
Lymph Node Ratio as a Prognosticator in SE Asia
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Table 1. Patient, tumor characteristics and treatment along with the unadjusted Hazard Ratio for all cause mortality.
Variable N (%) Unadjusted HR (95% CI) P value of unadjusted HR
Age in years ,0.001
Median (Range) 50 (22 to 87)
,40 years 225 (14.2%) 1
40 to 49 years 569 (35.8%) 0.7 (0.5 to 0.9)
50 to 59 years 470 (29.6%) 1.0 (0.8 to 1.3)
$60 years 325 (20.5%) 1.2 (0.9 to 1.6)
Year of diagnosis 0.76
1990–2000 521 (32.8%) 1
2001–2007 1068 (67.2%) 1.0 (0.8 to 1.2)
Place of Diagnosis ,0.001
Kuala Lumpur 1015 (63.8) 1
Singapore 574 (26.2%) 0.4 (0.3 to 0.5)
Ethnicity 0.005
Chinese 1064 (67.0%) 1
Malay 303 (19.1%) 1.2 (1.0 to 1.5)
Indian 176 (11.1%) 1.5 (1.1 to 1.9)
Other 46 (2.9%) 0.8 (0.4 to 1.6)
ER status* ,0.001
Negative 662 (44.0%) 1
Positive 844 (56.0%) 0.5 (0.4 to 0.7)
Unknown 83 0.8 (0.5 to 1.1)
PR Status* ,0.001
Negative 596 (45.7%) 1
Positive 706 (54.3%) 0.4 (0.3 to 0.6)
Unknown 287 0.8 (0.6 to 1.0)
Grade* ,0.001
Low 89 (6.2%) 0.4 (0.2 to 0.7)
Moderate 699 (49.1%) 1
High 635 (44.6%) 1.4 (1.1 to 1.6)
Unknown 166 1.0 (0.7 to 1.4)
Tumor size* ,0.001
#2 cm 381 (26.0%) 0.5 (0.4 to 0.7)
2.1–5 cm 868 (59.3%) 1
.5 cm 214 (14.6%) 1.6 (1.3 to 2.0)
Unknown 126 0.8 (0.6 to 1.1)
Radiotherapy ,0.001
No 430 (26.9%) 1
Yes 1159 (72.9%) 0.7 (0.5 to 0.8)
Chemotherapy ,0.001
No 246 (15.5%) 1
Yes 1343 (84.5%) 0.5 (0.4 to 0.6)
Hormone Therapy ,0.001
No 560 (35.2%) 1
Yes 1029 (64.8%) 0.5 (0.4 to 0.6)
Regional nodes examined 0.151
Median 15
1–3 18 (1.1%) 1.8 (0.9 to 3.3)
4–9 249 (15.7%) 1.0 (0.8 to 1.2)
$10 1322 (83.2%) 1
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versus those who survived).The NRI is similar to the percentage
reclassified but distinguishes between movements in the correct
direction (patients moving up the risk categories for event patients
(deaths) and down for nonevent patients (survivors)) [16]. Any
upward movement in risk categories for subjects with the event
(death) implies improved classification, and any downward
movement indicates worse reclassification. The interpretation is
opposite for subjects without the event (death).
The NRI is calculated as follows:
Pup,event = number of events moving up/number of events.
Pdown,event = number of events moving down/number of
events.
Pup,nonevent = number of nonevents moving up/number of non
events.
Pdown,nonevent = number of nonevents moving down/number of
non events.
NRI = (Pup,event - Pdown,event) – (Pup,nonevent - Pdown,nonevent).
Where ‘‘up’’ refers to the patients moving up in the risk
categories based on the new model when being compared to the
old model and ‘‘down’’ refers to the patients moving down in the
risk categories based on the new model when being compared to
the old model.
In order to estimate Pup,event, Pdown,event, Pup,nonevent,
Pdown,nonevent, we first determined the the predicted survival
probability for each patient based on models A and B. Based on
this predicted survival probability patients were categorized into
tertiles corresponding to low, intermediate and high risk of death
at 3 years of follow up. The majority of the patients were correctly
classified by both the models (as indicated by a high proportion of
patients falling on the diagonals in the risk classification table).
After a recent publication suggested that LNR is particularly
informative in subgroups of patients (i.e. patients with unfavorable
tumor characteristics and younger patients) we performed
subgroup analyses by age (,60 years and $60 years), receptor
status (ER- vs ER+) and grade (1, 2 and 3) [10]. For each
subgroup, two models were built as mentioned above.
All analyses were performed using STATA version 11.
Results
According to the LNR classification, 758 (47.7%) patients were
categorized as low category (.0 and ,0.2), 574 (36.1%) as
intermediate category (0.2 to 0.65) and 257 (16.2%) as high
category (.0.65 to 1) LNR corresponding to low, intermediate
and high risk of death respectively. For classic pN staging, 879
(55.2%) were pN1, 447 (28.1%) pN2 and 263 (16.7%) pN3
(Table 1). In all, 605 (38%) deaths were reported for the 1589
patients.
Five year survival probabilities for the patients categorized by
LNR were 79%, 70% and 43% for low, intermediate and high
Table 1. Cont.
Variable N (%) Unadjusted HR (95% CI) P value of unadjusted HR
Regional nodes positive (pN Stage) ,0.001
Median 3
1–3 879 (55.2%) 1
4–9 447 (28.1%) 1.7 (1.4 to 2.1)
$10 263 (16.7%) 3.3 (2.6 to 4.1)
Lymph Node Ratio ,0.001
Median 0.22
0.01–0.2 758 (47.7%) 1
0.201–0.65 574 (36.1%) 1.5 (1.2 to 1.8)
0.651–1 257 (16.2%) 3.6 (2.9 tp 4.5)
*indicates valid proportions have been calculated (i.e., not considering unknown).
doi:10.1371/journal.pone.0045809.t001












pN Stage 0.72 (0.70 to 0.75)
pN1 879 (55.2%) 256 79.0% (75.6% to 82.4%) 1 1
pN2 447 (28.1%) 198 65.0% (59.0% to 71.0%) 1.7 (1.4 to 2.1) 1.9 (1.5 to 2.3)
pN3 263 (16.7%) 151 48.0% (43.2% to 52.8%) 3.3 (2.6 to 4.1) 3.0 (2.4 to 3.7
Lymph Node Ratio 0.73 (0.71 to 0.76)
Low #0.20 758 (47.7%) 213 79.0% (75.4% to 82.6%) 1 1
Intermediate .0.20 to #0.65 574 (36.1%) 228 70.0% (65.2% to 74.8%) 1.5 (1.2 to 1.8) 1.5 (1.2 to 1.9)
High .0.65 257 (16.2%) 164 43.0% (33.0% to 53.0%) 3.6 (2.9 to 4.5) 3.2 (2.6 to 4.0)
*Model A is adjusted for: age, radiotherapy, surgery type, grade and tumor size and pN stage and stratified by ER Status. Model B is adjusted for: age, radiotherapy,
surgery type, grade and tumor size and LNR and stratified by ER Status. Both models were internally validated using bootstrap resampling.
doi:10.1371/journal.pone.0045809.t002
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category LNR groups respectively (Table 2). Five year survival
probabilities for the patients categorized by pN classification were
79%, 65% and 48% for pN1, pN2 and pN3 respectively.
Prediction Models
In univariate Cox regression analysis, age at diagnosis, place of
diagnosis, year of diagnosis, ethnicity, receptor status (ER and PR),
treatment, grade, stage, tumor size, pN staging were indepen-
dently and significantly associated with all cause mortality
(Table 1). After multivariate analysis, a model consisting of pN,
age, tumor size, tumor grade, chemotherapy, radiotherapy, and
surgery, gave the best fit. Taking pN1 patients as a reference,
adjusted mortality risks (Hazard Ratios) were 1.9 (95%CI, 1.5 to
2.3) for pN2 patients and 3.0 (95%CI, 2.4 to 3.7) for pN3 patients.
Similarly, compared to patient classified as low risk LNR (.0 and
,0.2), those with intermediate risk LNR had an HRadj of 1.5
(95%CI, 1.2 to 1.9) and those with high risk LNR an HRadj of 3.2
(95%CI, 2.6 to 4.0) (Table 2).
Discrimination and caliberation of prediction models
Both models A (base model plus pN) and B (base model plus
LNR) were well calibrated (p-value Hosmer Lemeshow test 0.67
and 0.83 respectively). In terms of discriminating ability, both
models performed equally well, as shown by the c statistic for
model A of 0.72 (95% CI 0.70 to 0.75) and c statistic for the model
B of 0.73 (95% CI 0.71 to 0.76). The substantial overlap between
the two 95% confidence intervals indicated that LNR did not
provide any added prognostic value when compared to pN staging
in predicting all cause mortality.
Net Reclassification Improvement of Patients Based on
the Prediction Models
Based on individual predicted survival probabilities (from both
pN staging and LNR models), when patients were categorized into
tertiles of low, intermediate and high risk of death, the LNR model
reclassified an additional 8.0% (n= 49) of patients with the event
(death) into high risk groups and incorrectly reclassified 4.5%
(n= 29) of the patients with the event into low risk groups. Among
the patients without the event (alive), an additional 5.6% (n= 52)
of patients were reclassified into low risk groups while 5.7%
(n= 53) of the patients without the event were reclassified into high
risk (Table 3).
Subgroup analysis showed that LNR was superior to pN staging
in categorizing patients’ risk of death for patients aged 60 years
and above, patients with ER negative tumors and patients with
high grade tumors, as in, for these subgroups, 95% confidence
intervals (CIs) for intermediate and high risk LNR groups did not
overlap while they did for the pN2 and pN3 categories. However,
in terms of discriminating ability, models for all subgroup analyses
including LNR performed as well as the models including pN
respectively, as attested by the c statistics and largely overlapping
95% CIs (Table 4). There was no significant difference in between
LNR and pN staging in terms of risk categorization for women
aged less than 60 years, patients with ER positive tumors and
patients with low and moderate grade tumors (Table S1).
Although a majority of the patients (,83%) did have at least ten
lymph nodes examined, about 17% of the patients had less than 10
nodes removed during axillary dissection. We performed a
subgroup analysis to assess the added prognostic value of LNR
for patients with less than 10 nodes retrieved but even for this
subset of patients, both pN staging and LNR predicted all cause
mortality equally well (data not shown). Different cut offs for LNR
were tested for the entire dataset but no new cut offs of LNR for
South East Asian patients were established.
Discussion
This study shows that pN staging as well as the LNR are
comparable in predicting overall survival of women with breast
cancer, except for patients aged 60 or more, patients with ER
negative tumors and patients with high grade tumors. Here, LNR
was superior in categorizing patients into intermediate and high
risk strata as compared to pN stage. However, in combination with
other prognostic factors, LNR did not provide any additional
prognostic information over pN staging, neither for the entire
cohort, nor for the subgroups of older women and those with ER
negative of grade 3 disease. The fact that LNR was not superior to
the pN staging was seen in other Asian studies as well [10]. A non
significant Net Reclassification Index for the LNR model
Table 3. Risk reclassification table at 3 years of follow up based on models including pN stage and LNR respectively.
As per model A (with pN)
Low risk of death
Intermediate risk
of death High risk of death Total
For patients with
the event (Dead)
Low risk of death 127 24 151
Intermediate risk of death 23 335 25 383
High risk of death 6 65 21
Total 150 365 90 605
As per model B (with LNR)
For patients without the
event (alive)
Low risk of death 405 45 450
Intermediate risk of death 48 396 8 452
High risk of death 4 16 20
Total 453 445 24 922
Net Reclassification Index (NRI) = 3.2% (p value 0.08). Patients are categorized into risk categories of death based on their individual survival probabilities obtained from
models A and B such that a patient with a high survival probability is categorized into the ‘low risk of death’ group and so on.
doi:10.1371/journal.pone.0045809.t003
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compared to the pN model suggested that both LNR and pN stage
were equally good at classifying patients into appropriate risk
strata based on whether they experienced the event (death) or not.
There are several independent but interrelated prognostic
factors that predict for recurrence and survival of breast cancer
patients. These include amongst others, tumor size, axillary nodal
status, histopathology, steroid receptors, HER 2 status, prolifer-
ative rate, ploidy, and oncogene amplification [17]. One of the
strongest prognostic indicators for breast cancer is number of
positive axillary nodes [18]. Furthermore, there is a direct
relationship between the number of involved axillary nodes and
the risk for distant recurrence [17].
The number of lymph nodes retrieved and examined is highly
dependent on surgical expertise, the institution’s protocol and the
pathologists’ experience [19]. Removal of at least ten axillary
lymph nodes is considered adequate for reliable lymph node
staging [20,21,22]. In the current study, 17% of the patients had
less than 10 nodes removed during axillary dissection. Even for
this subset of patients, both LNR and pN staging performed
equally well in predicting all cause mortality and there was no
significant difference in the discriminative power of the two
multivariate models (one with LNR and one with pN).
Results from our study showed that LNR and pN were equally
good at predicting all cause mortality overall but within certain
subgroups (ER negative patients, patients aged 60 years or more
and patients with high grade tumors), LNR was better at
categorizing patients into risk categories. The intermediate
category LNR was truly intermediate for these subgroups, i.e.,
the 95% Confidence Interval (CI) of the Hazard Ratio overlapped
neither the low nor the high category LNRs, whereas the pN2 and
Table 4. Subgroup analysis to check the added prognostic value of LNR over pN within specific subgroups.
Patients $60 years of age at diagnosis (N=325)
N (%) N Death (%) Unadj HR (95% CI) Adj HRa (95% CI) C statistic (95% CI)
pN stage 0.75 (0.70 to 0.81)
pN1 175 (53.8%) 53 (36.3%) 1 1
pN2 89 (27.4%) 51 (34.9%) 2.8 (1.8 to 4.1) 2.7 (1.8 to 4.1)
pN3 61 (18.8%) 42 (28.8%) 4.2 (2.7 to 6.3) 4.2 (2.6 to 6.7)
Lymph Node Ratio 0.76 (0.71 to 0.80)
Low #0.20 147 (45.2%) 44 (30.1%) 1 1
Intermediate .0.20 to #0.65 112 (34.5%) 51 (34.9%) 1.6 (1.0 to 2.4) 1.8 (1.1 to 2.7)
High .0.65 66 (20.3) 51 (34.9%) 5.2 (3.4 to 7.8) 4.5 (2.8 to 7.0)
Patients with ER negative tumors at diagnosis (N=662)
N (%) N Death (%) Unadj HR (95% CI) Adj HRb (95% CI) C statistic (95% CI)
pN stage 0.84 (0.80 to 0.87)
pN1 339 (51.2%) 100 (36.0%) 1 1
pN2 206 (31.1%) 106 (38.1%) 2.0 (1.5 to 2.6) 2.0 (1.5 to 2.7)
pN3 117 (17.7%) 72 (25.9%) 3.1 (2.3 to 4.3) 3.0 (2.1 to 4.1)
Lymph Node Ratio 0.85 (0.81 to 0.88)
Low #0.20 304 (45.9%) 93 (33.6%) 1 1
Intermediate .0.20 to #0.65 233 (35.2%) 95 (33.9%) 1.4 (1.0 to 1.9) 1.5 (1.1 to 2.0)
High .0.65 125 (18.9%) 90 (32.5%) 3.7 (2.7 to 4.9 3.5 (2.5 to 4.8)
Patients with high grade tumors at diagnosis (N=635)
N (%) N Death (%) Unadj HR (95% CI) Adj HRc (95% CI) C statistic (95% CI)
pN stage 0.76 (0.72 to 0.80)
pN1 320 (50.4%) 109 (40.1%) 1 1
pN2 180 (28.3%) 84 (30.9%) 1.6 (1.2 to 2.1) 1.7 (1.2 to 2.3)
pN3 135 (21.3%) 79 (29.0%) 2.6 (1.9 to 3.5) 2.6 (1.9 to 3.5)
Lymph Node Ratio 0.76 (0.72 to 0.81)
Low #0.20 286 (45.0%) 100 (36.9%) 1 1
Intermediate .0.20 to #0.65 229 (36.1%) 94 (34.7%) 1.3 (1.0 to 1.7) 1.4 (1.1 to 1.8)
High .0.65 120 (18.9%) 77 (28.4%) 2.9 (2.1 to 3.1) 2.7 (2.0 to 3.7)
aModel adjusted for age at diagnosis, chemotherapy, radiotherapy, surgery type, grade and tumor size and stratified by ER status.
bModel adjusted for age at diagnosis, chemotherapy, surgery type and tumor size.
cModel adjusted for age at diagnosis, chemotherapy, radiotherapy, surgery type and tumor size and stratified by ER status. All models were internally validated using
bootstrap resampling.
doi:10.1371/journal.pone.0045809.t004
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pN3 CIs overlapped (Table 4). Thus in multivariate analyses,
classification using the LNR provided well balanced nonoverlap-
ping risk groups, whereas classification using pN provided poorly
separated risk groups with overlapping hazard ratios for these
subgroup of patients. However, when comparing the c statistics for
the pN and LNR models for each of the subgroups respectively,
there was no significant difference. This suggested that LNR did
not provide any added prognostic value over pN stage for these
subgroup of patients as well.
Recent studies have indicated that full axillary clearance
following a positive sentinel node biopsy does not affect survival
in certain (low risk) categories of breast cancer patients [23,24].
These studies may induce a shift towards less axillary clearances
following sentinel node biopsy in the future. However, in many
low and middle income countries, sentinel node biopsies are not
routinely available. Also, Asian women present with more
advanced disease, larger tumor sizes, more nodal metastasis and
more high grade tumors, and therefore complete axillary
dissection is still very relevant in the South East Asian [14].
We acknowledge that our study suffers from several shortcom-
ings, including a relatively short follow up time. In addition, we
assessed all cause mortality as our end point as no data on cause of
death was available. This could have led to a mixing of effects as
this analysis allowed for competing risks of death. Also, additional
information on HER2/NEU receptor status, socioecomonic status
and comorbidity could have allowed for a deeper understanding of
the association.
Conclusion
Among South East Asian breast cancer patients, both the
Lymph Node Ratio and the pN staging system seem to be equally
good at predicting all cause mortality based on the cut offs used for
LNR in this study. LNR may be better than pN in dividing tumors
into high vs low risk for certain subgroup of patients, but LNR has
no added prognostic value over pN staging in addition to other
prognosticators.
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